ОБ ЭТОМ ЭПИЗОДЕ
Chronic inflammatory demyelinating polyneuropathy (CIDP) presents significant challenges in both diagnosis and long-term disease management. As consensus definitions, emerging targeted therapies, and research into serologic biomarkers evolve, how can clinicians optimize individual care algorithms?
In this follow-up discussion, Karissa Gable, MD, Duke University Medical Center, breaks down recent breakthroughs in CIDP care and trial design:
- Standardizing CIDP Terminology: Key updates from the new international consensus definitions paper establishing unified criteria for disease remission, stability, treatment response, and refractory disease.
- The Emerging Pipeline: What’s next in therapeutic development, including FcRn antagonists (nipocalimab and batoclimab) and complement inhibitors.
- Shared Decision-Making: Practical strategies for tailoring therapy selection based on patient preferences, lifestyle, comorbidities, and administration routes.
- Building Confidence in CIDP Care: Applying 2021 EAN/PNS guidelines to navigate diagnosis and ongoing treatment adjustments when first-line options fall short.
💡 Complete the Educational Activity: https://bit.ly/4pPcVWe
👉 Access the accompanying slide deck for comprehensive guidance on CIDP detection and management: https://bit.ly/4pPcVWe
In this follow-up discussion, Karissa Gable, MD, Duke University Medical Center, breaks down recent breakthroughs in CIDP care and trial design:
- Standardizing CIDP Terminology: Key updates from the new international consensus definitions paper establishing unified criteria for disease remission, stability, treatment response, and refractory disease.
- The Emerging Pipeline: What’s next in therapeutic development, including FcRn antagonists (nipocalimab and batoclimab) and complement inhibitors.
- Shared Decision-Making: Practical strategies for tailoring therapy selection based on patient preferences, lifestyle, comorbidities, and administration routes.
- Building Confidence in CIDP Care: Applying 2021 EAN/PNS guidelines to navigate diagnosis and ongoing treatment adjustments when first-line options fall short.
💡 Complete the Educational Activity: https://bit.ly/4pPcVWe
👉 Access the accompanying slide deck for comprehensive guidance on CIDP detection and management: https://bit.ly/4pPcVWe
английский
США
РАСШИФРОВКА 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
ПОИСК ПРОШЛЫХ ЭПИЗОДОВ
Искать прошлые эпизоды Oncology Data Advisor.
ДРУГИЕ ЭПИЗОДЫ В ЭТОМ ПОДКАсте
Read the full article here! https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging
As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing pati…
What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies?
In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO t…
Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient?
In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred H…
Read the full article here: https://oncdata.com/information-overload-and-the-portal-patient
The way that patients receive medical information has changed dramatically. Through electronic health record portals, laboratory values, imaging reports, and pathology results often become available the mo…
Отказ от ответственности: Подкаст и иллюстрации, встроенные в эту страницу, взяты из i3 Health, который является собственностью его владельца и не связан или не одобрен Listen Notes, Inc.
ИЗМЕНИТЬ
Спасибо, что помогаете поддерживать базу подкастов актуальной.
